SCHEMBL4473516

SCHEMBL4473516

Cc1ccc(CNS(=O)(=O)c2cccc3c(O)cccc23)o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EDNRA P25101 1/20 0.47
CDK2 P24941 1/20 0.44
TP53 P04637 1/20 0.42
NSD2 O96028 9/20 0.41
ALDH1A1 P00352 3/20 0.41
MAPT P10636 2/20 0.41
PKM P14618 1/20 0.41
LMNA P02545 1/20 0.41
MAPK1 P28482 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
POLB P06746 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
ALOX12 P18054 1/20 0.40
HCRTR1 O43613 1/20 0.39
PGAM1 P18669 1/20 0.39
KMT2A Q03164 2/20 0.39
RXFP1 Q9HBX9 2/20 0.39
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4452543 0.85 NSD2 (0.60) EDNRATP53NSD2
Hydrochloric Acid SCHEMBL4453009 0.84 NSD2 (0.61) EDNRATP53NSD2
SCHEMBL4449108 0.82 EDNRA (0.52) EDNRATP53NSD2ALDH1A1MAPT
SCHEMBL4479454 0.78 CYP19A1 (0.42) TP53ALDH1A1PKMPOLBKMT2A
SCHEMBL4492415 0.76 ALDH1A1 (0.55) EDNRACDK2NSD2ALDH1A1HPGD
SCHEMBL4479900 0.76 KMT2A (0.50) TP53NSD2ALDH1A1MAPTLMNA
SCHEMBL4483905 0.75 NSD2 (0.69) CDK2NSD2ALDH1A1MAPK1
SCHEMBL4489080 0.73 NSD2 (0.49) EDNRACDK2TP53NSD2ALDH1A1
SCHEMBL4491082 0.73 NSD2 (0.57) CDK2NSD2
SCHEMBL4481450 0.73 NSD2 (0.52) CDK2NSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US claimed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 US claimed
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US disclosed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215645-A1 Amide derivatives OGG1, HDAC1, BCL2A1 EDNRA 756/4885CDK2 802/4885TP53 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.